Sign up
Pharma Capital

Q BioMed licenses significant biomarker to diagnose glaucoma

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive Investors the New York-based biotech accelerator has licensed a biomarker from Washington University called GDF15 to monitor glaucoma severity and progression.

Corin says the diagnostic is a 'significant advancement' and the company will soon be announcing the roll-out of a diagnostic kit. The company is also developing a molecule called MAN-01, for the treatment of glaucoma.

 

View full QBIO profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.